Neuroprotective response after photodynamic therapy: Role of vascular endothelial growth factor

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Suzuki, Misa ^a,b   Ozawa, Yoko ^a   Kubota, Shunsuke ^a   Hirasawa, Manabu ^a   Miyake, Seiji ^a   Noda, Kousuke ^c   Tsubota, Kazuo ^a   Kadonosono, Kazuaki ^b   Ishida, Susumu ^a,c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Akt; Bax; Neuroprotection; Pdt; Retina; Vegf

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VEGFR1 FC FRAGMENT FUSION PROTEIN; NEUROPROTECTIVE AGENT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL STRESS; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LASER; MOUSE; NEUROPROTECTION; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTORECEPTOR CELL; PROTEIN EXPRESSION; RETINA; UPREGULATION; ANIMAL; C57BL MOUSE; CYTOLOGY; DRUG ANTAGONISM; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; PHOTOCHEMOTHERAPY; PHYSIOLOGY; RADIATION EXPOSURE; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; LASERS; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOTOCHEMOTHERAPY; PROTO-ONCOGENE PROTEINS C-AKT; RETINA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 83455203275     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-176     Document Type: Article

References (43)

1. Folkman J. Successful treatment of an angiogenic disease. N Engl J Med 1989, 320:1211-1212. 10.1056/NEJM198905043201811, 2469017.
2. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9(Suppl 1):2-10.
3. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, . Ianchulev TASG Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009, 116:57-65. e55, 10.1016/j.ophtha.2008.10.018, 19118696, Ianchulev TASG.
4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1419-1431. 10.1056/NEJMoa054481, 17021318.
5. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004, 351:2805-2816. 10.1056/NEJMoa042760, 15625332.
6. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845. 10.1038/359843a0, 1279431.
7. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994, 331:1480-1487. 10.1056/NEJM199412013312203, 7526212.
8. Izumi-Nagai K, Nagai N, Ohgami K, Satofuka S, Ozawa Y, Tsubota K, Umezawa K, Ohno S, Oike Y, Ishida S. Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization. Arterioscler Thromb Vasc Biol 2007, 27:2555-2562. 10.1161/ATVBAHA.107.151431, 17932319.
9. Nagai N, Oike Y, Izumi-Nagai K, Urano T, Kubota Y, Noda K, Ozawa Y, Inoue M, Tsubota K, Suda T, Ishida S. Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Biol 2006, 26:2252-2259. 10.1161/01.ATV.0000240050.15321.fe, 16888236.
10. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003, 44:2155-2162. 10.1167/iovs.02-0807, 12714656.
11. Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, Hida T, Oguchi Y, Ambati J, Miller JW, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003, 198:483-489. 10.1084/jem.20022027, 2194095, 12900522.
12. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439. 10.1038/380435a0, 8602241.
13. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA 2009, 106:18751-18756. 10.1073/pnas.0905010106, 2774033, 19841260.
14. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorselink M, Heymans S, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001, 28:131-138. 10.1038/88842, 11381259.
15. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007, 171:53-67. 10.2353/ajpath.2007.061237, 1941589, 17591953.
16. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999, 117:1329-1345.
17. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Ophthalmology 2001, 108:841-852.
18. Husain D, Kramer M, Kenny AG, Michaud N, Flotte TJ, Gragoudas ES, Miller JW. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 1999, 40:2322-2331.
19. Marmur ES, Schmults CD, Goldberg DJ. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg 2004, 30:264-271. 10.1111/j.1524-4725.2004.30083.x, 14871220.
20. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003, 136:1049-1061.
21. Photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD): results of the Japanese AMD Trial (JAT) extension. Jpn J Ophthalmol 2008, 52:99-107.
22. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003, 44:4473-4480. 10.1167/iovs.02-1115, 14507895.
23. Kaiser PK, Boyer DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Mieler W, Slakter JS, Samuel M, Tolentino MJ, et al. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009, 116:747-755. 755 e741, 10.1016/j.ophtha.2008.12.057, 19243834.
24. Yoko Ozawa KT, Hideyuki O. Encyclopedia of the Eye. ELSEVIER 2010,
25. Ray PS, Jia J, Yao P, Majumder M, Hatzoglou M, Fox PL. A stress-responsive RNA switch regulates VEGFA expression. Nature 2009, 457:915-919. 10.1038/nature07598, 2858559, 19098893.
26. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, Greenberg DA. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 2003, 111:1843-1851. 161428, 12813020.
27. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002, 22:RC216.
28. Kubota S, Kurihara T, Ebinuma M, Kubota M, Yuki K, Sasaki M, Noda K, Ozawa Y, Oike Y, Ishida S, Tsubota K. Resveratrol prevents light-induced retinal degeneration via suppressing activator protein-1 activation. Am J Pathol 177:1725-1731.
29. Matsubara A, Nakazawa T, Noda K, She H, Connolly E, Young TA, Ogura Y, Gragoudas ES, Miller JW. Photodynamic therapy induces caspase-dependent apoptosis in rat CNV model. Invest Ophthalmol Vis Sci 2007, 48:4741-4747. 10.1167/iovs.06-1534, 17898299.
30. Kubota S, Kurihara T, Mochimaru H, Satofuka S, Noda K, Ozawa Y, Oike Y, Ishida S, Tsubota K. Prevention of ocular inflammation in endotoxin-induced uveitis with resveratrol by inhibiting oxidative damage and nuclear factor-kappaB activation. Invest Ophthalmol Vis Sci 2009, 50:3512-3519. 10.1167/iovs.08-2666, 19279313.
31. Kurihara T, Ozawa Y, Nagai N, Shinoda K, Noda K, Imamura Y, Tsubota K, Okano H, Oike Y, Ishida S. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 2008, 57:2191-2198. 10.2337/db07-1281, 2494692, 18487452.
32. Kilic E, Kilic U, Wang Y, Bassetti CL, Marti HH, Hermann DM. The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB J 2006, 20:1185-1187. 10.1096/fj.05-4829fje, 16641198.
33. Kovacs Z, Ikezaki K, Samoto K, Inamura T, Fukui M. VEGF and flt. Expression time kinetics in rat brain infarct. Stroke 1996, 27:1865-1872. discussion 1872-1863, 10.1161/01.STR.27.10.1865, 8841346.
34. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003, 34:383-394. 10.1038/ng1211, 12847526.
35. Greenberg DA, Jin K. From angiogenesis to neuropathology. Nature 2005, 438:954-959. 10.1038/nature04481, 16355213.
36. Pucci S, Mazzarelli P, Missiroli F, Regine F, Ricci F. Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon. Prog Brain Res 2008, 173:555-573.
37. Yamaguchi H, Wang HG. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 2001, 20:7779-7786. 10.1038/sj.onc.1204984, 11753656.
38. Xin M, Deng X. Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem 2005, 280:10781-10789. 10.1074/jbc.M500084200, 15642728.
39. Matheny RW, Adamo ML. Current perspectives on Akt Akt-ivation and Akt-ions. Exp Biol Med (Maywood) 2009, 234:1264-1270.
40. Fedorenko GM, Fedorenko YP, Fedorenko AG, Uzdensky AB. Dynamics of ultrastructural alterations in photosensitized crayfish glial and neuronal cells: Structures involved in transport processes and neuroglial interactions. J Neurosci Res 2011,
41. Fedorenko GM, Uzdensky AB. Dynamics of ultrastructural changes in the isolated crayfish mechanoreceptor neuron under photodynamic impact. J Neurosci Res 2008, 86:1409-1416. 10.1002/jnr.21587, 18061942.
42. Kim IK, Husain D, Michaud N, Connolly E, Lane AM, Durrani K, Hafezi-Moghadam A, Gragoudas ES, O'Neill CA, Beyer JC, Miller JW. Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci 2006, 47:357-363. 10.1167/iovs.04-0087, 16384985.
43. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004, 5:497-508. 10.1016/S1470-2045(04)01529-3, 15288239.